Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
DNA from air could revolutionize the way we measure animal biodiversity
On Jan. 6, 2022, two new studies published in the journal Current Biology showed that environmental DNA (eDNA)…
Merck and Ridgeback announced U.K. Government to purchase additional 1.75 million courses of molnupiravir
On Dec. 22, 2021, Merck and Ridgeback Biotherapeutics announced that the United Kingdom Government agreed to purchase an…
Moderna announced supply agreement with the UK for additional 60 million doses of COVID-19 vaccine in 2022 and 2023
On Dec. 1, 2021, Moderna announced a revised supply agreement with the UK government for up to 60…
Novavax filed for authorization of its COVID-19 vaccine in the United Kingdom
On Oct. 27, 2021, Novavax announced the completion of its rolling regulatory submission to the U.K. Medicines and…
Axcella Therapeutics launched clinical program to develop treatment for patients with long COVID
On Oct. 26, 2021, Axcella Therapeutics announced a new clinical program to investigate AXA1125 as a potential treatment…
UK authorized Regeneron antibody cocktail to prevent and treat acute COVID-19 infection
On Aug. 20, 2021, Regeneron announced that the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency had…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Therapeutics | Vaccine
Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections Survey
On Aug. 19, 2021, the University of Oxford reported that obtaining two vaccine doses remained the most effective…
Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variants
On Jul. 29, 2021, Cocrystal Pharma announced that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed…
SIGA announced collaboration with Oxford University to expanded Access Protocol for Use of TPOXX in Central African Republic
On Jul. 29, 2021, SIGA Technologies announced that it had entered into a collaboration with Oxford University in…
Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study
On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…
UKï¾’s MHRA accepted Humanigenï¾’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review
On Jul. 9, 2021, Humanigen announced its submission for Marketing Authorization for lenzilumab in COVID-19, begun in Jun….
SIGA supplied TPOXX (Tecovirimat) as compassionate treatment for Monkeypox case in the UK
On Jun. 30, 2021, SIGA Technologies announced that it had provided TPOXX (tecovirimat) to Liverpool University Hospitals NHS…
Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
Novavax announced participation in mix-and-match COVID-19 vaccine booster trial in the United Kingdom
On May 21, 2021, Novavax announced participation in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that led…
Ministry of Food and Drug Safety of South Korea authorized Moderna’s COVID-19 vaccine
On May 21, 2021, Moderna announced that the Ministry of Food and Drug Safety of South Korea (MFDS)…
Complete trial results of Novavax COVID-19 investigational vaccine posted to preprint server medRxiv
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
US, Chile and Peru interim trial data showed Oxford-AstraZeneca vaccine was safe and highly effective
On Mar. 22, 2021, Oxford University announced that a Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted…
Novavax confirmed ligh levels of efficacy against original and variant COVID-19 strains in UK and South Africa trials
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
Novavax completed enrollment of PREVENT-19, COVID-19 vaccine pivotal phase 3 trial in the US and Mexico
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
Novavax and Government of Switzerland announced agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
OraSure’s OMNIgene-ORAL saliva collection kit selected by Chronomics for use in UK Government travel COVID-19 testing
On Jan. 26, 2021, OraSure Technologies announced that Chronomics had selected the OMNIgene-ORAL (OME-505) saliva collection device as…
Moderna COVID-19 vaccine retained neutralizing activity against emerging variants identified in UK and South Africa
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
Twist Bioscience began shipping of synthetic RNA controls for UK variant strain of SARS-CoV-2
On Jan. 14, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
T2 Biosystems T2SARS-CoV-2 panel proved effective with global rise in variants of the SARS-CoV-2 virus
On Jan. 11, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel – a molecular diagnostic test that detects…
UK medicines regulator approved Moderna vaccine as third COVID-19 vaccine
On Jan. 8, 2021, the COVID-19 vaccine developed by Moderna has today been given regulatory approval for supply…